Pharnext S.A. announced an update from its ongoing Phase III clinical program (PLEO-CMT and PLEO-CMT-FU studies) evaluating PXT 3003 (baclofen...
Odonate Therapeutics, Inc. announced positive top-line results from CONTESSA, a Phase III study of tesetaxel in patients with metastatic breast cancer (MBC).
Objective: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer, which accounts for 20 – 25% of cases of breast cancers, is highly aggressive. Due to cardiotoxicity and increasing resistance associated with...
Seagen Inc. announced that the European Commission (EC) has granted marketing authorization for Tukysa (tucatinib) in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer who have received at least two prior anti-HER2 treatment regimens.